Obvious concern here is distraction factor.Or may me thats the purpose ?
Core product yet to gain traction and they are adding another in a different clinical setting ? Two separate patient groups and refering physicians, probably not even in the same location/building given the way healthcare is delivered in the US, will this be / this will be a distraction.
How are the commercial guys - if they have any - going to target and prioritise.
Where the RSH story was clear and focused - if unproven - this confuses and dilutes. RSH need to be clear on their purpose.
Obvious concern here is distraction factor.Or may me thats the...
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.002(6.25%) |
Mkt cap ! $31.79M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.0¢ | 2.9¢ | $23.29K | 781.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20876 | 2.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 608207 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.0¢ |
Change
-0.002 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 3.0¢ | 3.0¢ | 2.8¢ | 110375 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| RSH (ASX) Chart |